The Greatest Achievements & Contributions
Since the beginning of the decade-long research activity of ABCSG, its main focus was as to whether better prognosis and treatment options for patients can be derived from new drugs, changes in dosage or even through extended deployment of different, innovative cancer therapies. In this context, ABCSG’s physicians have achieved remarkable successes.
90 % Breast Conservation
At ABCSG centers, patients with smaller tumors and without lymph node involvement can be treated with breast-conserving surgery in 90 % of all cases. This very positive development for the women affected is thanks to intensive research and the resulting new treatment options. The success rate in Austria is now three times higher as compared to the 1990s and, for example, significantly higher than in the USA.
Colorectal Branch of the ABCSG
ABCSG physicians have also achieved significant success in colorectal cancer. One of the most feared consequences of rectal cancer treatment is the need for an artificial bowel outlet after surgery. In the ABCSG centers focusing on studies in this area, the majority of patients are spared this fate, as the sphincter can be preserved in almost 90 % of cases.
The Colorectal Branch has also succeeded in developing a uniform standard of care for rectal cancer treatment. This ensures that patients throughout Austria receive treatment best tailored to the size and location of the tumor.
Task Force Pancreas
In 2010, the Task Force Pancreas was founded to standardize and, above all, optimize therapies in Austria. In September 2013, ABCSG first started clinical trials on pancreatic cancer. The initial project ABCSG P00 was characterized by a sensational recruitment. This perioperative study evaluated the effect of fibrin-coated collagen patch in reducing pancreatic fistula formation. It has been tested whether this could effectively prevent the development of leaks after partial resection of the pancreatic head and duodenum. The results were published in the “British Journal of Surgery” in 2018; unfortunately, the use of fibrin-coated collagen patch did not produce the desired effect.
The second pancreatic cancer study P02 is being conducted since 2017, investigating the value of neoadjuvant chemotherapy following radiochemotherapy in terms of R0 resectability. Several centers in Austria are participating in this complex trial. Further pancreas studies are already being planned.